These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 7591683

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
    Ludwig H, Cohen AM, Huber H, Nachbaur D, Jungi WF, Senn H, Günczler P, Schüller J, Eckhardt S, Seewann HL.
    Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
    [Abstract] [Full Text] [Related]

  • 3. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
    Ludwig H, Cohen AM, Polliack A, Huber H, Nachbaur D, Senn HJ, Morant R, Eckhardt S, Günczler P, Seewann HL.
    Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
    Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, Tarkovács G, Linkesch W, Maniatis A, Morant R, Drach J, Kuhn I, Schuster J, Hinke A.
    Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, Dimopoulos MA, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N, Maniatis A.
    Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
    [Abstract] [Full Text] [Related]

  • 12. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 13. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
    Ludwig H, Cortelezzi A, Scheithauer W, Van Camp BG, Kuzmits R, Fillet G, Peetermans M, Polli E, Flener R.
    Eur J Cancer Clin Oncol; 1986 Sep 15; 22(9):1111-6. PubMed ID: 3536528
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan 15; 124(2):212-22. PubMed ID: 8533996
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F.
    J Clin Oncol; 1991 Mar 15; 9(3):444-8. PubMed ID: 1999714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.